ArticleNature biotechnology2020
Overcoming barriers to early disease intervention.
Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.Cancer research communications · 2026Article
- Comprehensive multi-omics pan-cancer analysis revealed that ANTXR1 is a potential biomarker for diagnosis and immunotherapy.Biology direct · 2026Article
- Dynamics and Diversity of Microbial Community Succession During the Solid-State Fermentation Process of Fuzhuan Brick Sea Buckthorn Leaf Tea.Foods (Basel, Switzerland) · 2026Article
- Determinants of late malaria treatment among under-five children in West Africa.BMC pediatrics · 2026Article
- Metagenomic insights reveal β-glucosidase-producing lactic acid bacteria from Miyamikhri with taxiphyllin degradation potential.Scientific reports · 2026Article
- Schlafen 11 (SLFN11) overexpression and nucleolar localization in response to bortezomib in multiple myeloma.bioRxiv : the preprint server for biology · 2026Article
- Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma.Journal of translational internal medicine · 2026Article
- Gut microbiota profile and response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review.Translational gastroenterology and hepatology · 2026Review
- Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database.International journal of surgery (London, England) · 2026Article
- Mechanosensory Piezo2 regulated by gut microbiota participates in the development of visceral hypersensitivity and intestinal dysmotility.Gut microbes · 2025Article
- Decoding the Gut Microbiota in Multiple Sclerosis Using Nanopore Long-Read Sequencing: Insights into Disease Severity and Subtypes.Molecular neurobiology · 2025Article
- Characterizing Gut Microbiota Composition and Its Correlation with Growth Variation in Sea Cucumber Apostichopus japonicus.Marine biotechnology (New York, N.Y.) · 2025Article
- Long-Term Impact of the Largest Environmental Disaster in Latin America (Fundão Dam Failure) on Microbial Communities in Lakes of the Doce River Basin, Brazil.Environmental microbiology · 2025Article
- POCALI: Prediction and Insight on CAncer LncRNAs by Integrating Multi-Omics Data with Machine Learning.Small methods · 2025Article
- Article
- A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy.Frontiers in immunology · 2025Article
- Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy.Current cancer drug targets · 2025Article
- MTFAP: a comprehensive platform for predicting and analyzing master transcription factors.Scientific reports · 2024Article
- VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma.Experimental & molecular medicine · 2024Article
- GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma.Hepatology communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32444852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.